<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591834</url>
  </required_header>
  <id_info>
    <org_study_id>RGX-121-9101</org_study_id>
    <nct_id>NCT04591834</nct_id>
  </id_info>
  <brief_title>Mucopolysaccharidosis Type II Observational</brief_title>
  <official_title>A Prospective, Observational Study of Pediatric Patients With Neuronopathic Forms of MPS II (Hunter Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenxbio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regenxbio Inc.</source>
  <oversight_info>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study planned to document prospectively disease manifestation and&#xD;
      neurocognitive course in pediatric patients with a clinical presentation consistent with&#xD;
      neuronopathic (&quot;severe&quot;) MPS II undergoing current standard of care and/or intrathecal&#xD;
      Elaprase® for their condition. Some patients may be offered the opportunity to screen for a&#xD;
      gene therapy study conducted by the same sponsor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MPS II is a rare X-linked recessive genetic disease caused by mutations in the&#xD;
      iduronate-2-sulfatase gene (IDS). Enzyme replacement therapy (ERT) with recombinant&#xD;
      idursulfase (ELAPRASE®) is the only approved product for the treatment of Hunter syndrome;&#xD;
      however, ERT as currently administered does not cross the blood brain barrier and is&#xD;
      therefore unable to address the unmet need in MPS II patients with CNS (neurocognition and&#xD;
      behavior) involvement. This is an observational study to document prospectively disease&#xD;
      manifestation and neurocognitive course in pediatric patients with a clinical presentation&#xD;
      consistent with neuronopathic (&quot;severe&quot;) MPS II undergoing current standard of care for their&#xD;
      condition. Approximately forty pediatric subjects who have severe MPS II will be enrolled.&#xD;
      Changes in neurodevelopmental parameters of cognitive, behavioral, and adaptive function over&#xD;
      time will be the primary focus for a duration of 104 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in neurodevelopmental parameters of cognitive function over time</measure>
    <time_frame>104 weeks</time_frame>
    <description>Bayley Scales of Infant and Toddler Development Third Edition (BSID-III)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in neurodevelopmental parameters of cognitive function over time</measure>
    <time_frame>104 weeks</time_frame>
    <description>Mullen Scales of Early Learning (MSEL) Visual Reception Domain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in neurodevelopmental parameters of adaptive behavior function over time</measure>
    <time_frame>104 weeks</time_frame>
    <description>Vineland Adaptive Behavior Scales Second Edition (VABS-II)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in disease-specific biomarkers over time</measure>
    <time_frame>104 weeks</time_frame>
    <description>I2S activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in disease-specific biomarkers over time</measure>
    <time_frame>104 weeks</time_frame>
    <description>GAGs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>104 weeks</time_frame>
    <description>PedsQL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>104 weeks</time_frame>
    <description>ADL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Caregiver reported outcome</measure>
    <time_frame>104 weeks</time_frame>
    <description>Family Burden of Illness Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sleep</measure>
    <time_frame>104 weeks</time_frame>
    <description>SDSC</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mucopolysaccharidosis II</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>No Intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>An observational study in subjects with the severe form of MPS II.</description>
    <arm_group_label>Observational</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Up to 40 subjects ages 1 month to 8 years of age who have documented neurocognitive&#xD;
        deficits due to MPS II or who have a genotype and family history consistent with an&#xD;
        inherited form of severe MPS II will be invited to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meets any of the following criteria:&#xD;
&#xD;
               1. Has a clinical diagnosis of severe MPS II and has a documented mutation in IDS,&#xD;
                  OR&#xD;
&#xD;
               2. Has a relative clinically diagnosed with severe MPS II who has the same IDS&#xD;
                  mutation as the subject, OR&#xD;
&#xD;
               3. Has documented mutation(s) in IDS that in the opinion of the investigator is&#xD;
                  known to result in a neuronopathic phenotype&#xD;
&#xD;
          2. Has sufficient communication capacity to complete the required protocol testing&#xD;
&#xD;
        Patient's legal guardian must be willing and able to provide written, signed informed&#xD;
        consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has had prior treatment with an AAV-based gene therapy product&#xD;
&#xD;
          2. Is currently participating in a clinical trial of an investigational product for the&#xD;
             treatment of MPS II with the exception of IT ELAPRASE trials; no investigational&#xD;
             product may be taken starting 30 days or 5 half-lives of the investigational product&#xD;
             prior to signing the ICF, whichever is longer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>866-860-0117</phone>
    <email>MPSII@regenxbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco, Benioff Children's Hospital</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Paul Harmatz</last_name>
      <phone>925-639-6321</phone>
      <email>Jill.nicholas@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Dr. Paul Harmatz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Movsesyan</last_name>
      <phone>714-509-3008</phone>
      <email>NMovsesyan@choc.org</email>
    </contact>
    <investigator>
      <last_name>Raymond Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Bastinck</last_name>
      <phone>267-521-2355</phone>
      <email>bastinckh@chop.edu</email>
    </contact>
    <investigator>
      <last_name>Dr. Can Ficicioglu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothy McKelvey</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>23833</phone_ext>
      <email>dorothy.mckelvey@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. John Mitchell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPS II</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Hunter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

